Sun, Sep 21, 2014, 5:27 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

  • bluecheese4u bluecheese4u Aug 1, 2012 9:36 AM Flag

    Allergan Reports Second Quarter 2012 Operating Results

    Allergan Reports Second Quarter 2012 Operating Results

    (IRVINE, Calif., August 1, 2012) - Allergan, Inc. (NYSE: AGN) today announced operating results for the quarter ended June 30, 2012. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 13, 2012 to stockholders of record on August 23, 2012.

    Operating Results Attributable to Stockholders
    For the quarter ended June 30, 2012:

    Allergan reported $0.96 diluted earnings per share attributable to stockholders compared to $0.79 diluted earnings per share attributable to stockholders for the second quarter of 2011.
    Allergan reported $1.07 non-GAAP diluted earnings per share attributable to stockholders compared to $0.96 non-GAAP diluted earnings per share attributable to stockholders for the second quarter of 2011, an 11.5 percent increase.
    Product Sales
    For the quarter ended June 30, 2012:

    Allergan reported $1,467.4 million total product net sales. Total product net sales increased 4.8 percent compared to total product net sales in the second quarter of 2011. On a constant currency basis, total product net sales increased 8.7 percent compared to total product net sales in the second quarter of 2011.
    Total specialty pharmaceuticals net sales increased 5.0 percent, or 8.8 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the second quarter of 2011.
    Total medical devices net sales increased 4.0 percent, or 8.3 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2011.
    "In the second quarter, Allergan continued to deliver strong earnings growth in spite of the strong U.S. Dollar relative to virtually all major currencies," said David E.I. Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer. "In addition, we continue to focus on identifying efficiencies so that we can continue to invest strongly in R&D to drive innovation."

    Product and Pipeline Update
    During the second quarter of 2012:

    Allergan submitted an application with Health Canada seeking approval for the use of BOTOX® (onabotulinumtoxinA) as treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.
    Outlook
    For the full year of 2012, Allergan expects:

    Total product net sales between $5,650 million and $5,800 million.
    Total specialty pharmaceuticals net sales between $4,740 million and $4,850 million.
    Total medical devices net sales between $910 million and $950 million.
    ALPHAGAN® franchise product net sales between $420 million and $440 million.
    LUMIGAN® franchise product net sales between $620 million and $640 million.
    RESTASIS® product net sales between $750 million and $780 million.
    BOTOX® product net sales between $1,760 million and $1,800 million.
    LATISSE® product net sales at approximately $100 million.
    Breast aesthetics product net sales between $360 million and $380 million.
    Obesity intervention product net sales at approximately $170 million.
    Facial aesthetics product net sales between $380 million and $400 million.
    Non-GAAP cost of sales to product net sales ratio at approximately 14%.
    Non-GAAP other revenue at

    http://agn360.client.shareholder.com/releasedetail.cfm?ReleaseID=697079

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AGN
168.21-1.76(-1.04%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.